AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT01921114 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Bard® Dual-Lumen PowerPICC SOLO2®
Study NCT01226485 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Taladegib
Description: Administered IV
Study NCT01765452 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Closone
Description: 75mg/100mg, 8weeks, PO
Study NCT01765452 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Plavix with Astrix
Description: 75mg, 100mg a day, 8weeks, PO
Study NCT01181219 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: CXL without epithelial removal
Description: UV-radiation of a Riboflavin saturated cornea without prior epithelial removal
Study NCT01181219 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: CXL with epithelial removal
Description: UV-radiation of a Riboflavin saturated cornea after surgical epithelial removal has been performed
Study NCT01827098 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Endodontic Regeneration
Description: Blood clot formation is induced in the root canal after disinfection. Collagen material is placed over the clot. The canal access is sealed with white MTA and glass ionomer restoration. Permanent restoration is placed 3 months later on top of the MTA.
Study NCT01531907 — intervention group
Intervention type: OTHER
Intervention: Study visit procedures
Description: Anthropometric measurements to include:~* Weight, height, and BMI.~* Waist and hip circumference~* Triceps skinfold thickness~* Measurement of supine abdominal thickness A baseline blood sample (15ml)is taken before receiving a standard polycal drink (75g glucose load) Three further blood samples (15 ml) will be taken, at the time points 20, 60 and 120 minutes after glucose loading. In 10 subjects (5 lean and 5 obese) we will take an additional blood sample (up to 50 ml) at baseline into heparin to grow osteoclasts in culture. Visit duration - approximately 3-4 hours.
Study NCT04162236 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: Ecocardiographyc ultrasound
Description: * Epidemiological data: Maternal history risk factors. First trimester scan is performed on all patients.~* Antropomethric measures~* Systemic arterial stiffness: using applanation tonometry with pulse wave analysis and pulse wave velocity.~* Carotid Intima Thickness~* Echocardiography assessment: It will be performed by a cardiologist specialized in cardiac imaging according to the usual standard protocol. High resolution images will be acquired and post-processed with dedicated software for the speckle tracking analysis. 2D echocardiography parameters to be acquired, tissue Doppler and speckle tracking software~* Markers in maternal blood: Angiogenic factor and cardiac function biomarkers: Blood samples will be collected without anticoagulant to obtain serum. sFLT-1, PlGF, High-sensitivity Troponin and NT-proBNP will be measured using automated electrochemiluminescence immunoassays.
Study NCT04104087 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: tunneling technique with sub epithelial connective tissue graft or deepithelialized free gingival graft.
Description: enhancing papillary hight and treating gingival recession RT2 by performing tunneling technique with sub epithelial connective tissue graft or deepithelialized free gingival graft.
Study NCT04794114 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: experimental ankle foot orthosis
Description: On the basis of an accurate kinetic and kinematic analysis, a customized orthosis in thermoplastic material with carbon inserts will be created that will make the brace more elastic and facilitate the child's motor activities.
Study NCT00566839 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: awake nonresectional LVRS
Description: Thoracoscopic nonresectional lung volume reduction surgery carried out in awake patients under sole epidural anesthesia through plication of most emphysematous target areas of the lung
Study NCT00566839 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Nonawake resectional LVRS
Description: Thoracoscopic lung volume reduction surgery carried out under general anesthesia and one-lung ventilation through nonanatomic resection of the most emphysematous target areas of the lung
Study NCT00002721 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: doxorubicin hydrochloride
Study NCT00002721 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: estramustine phosphate sodium
Study NCT00002721 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: drug resistance inhibition treatment
Study NCT00812721 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Preservative Free Saline
Description: One drop will be instilled into each eye once
Study NCT04794114 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: traditional ankle foot orthosis
Description: The normal afos in thermoplastic material, while guaranteeing an ankle joint stability, make the joint more rigid and reduce the elasticity of movement especially during running, jumping and sprinting.
Study NCT00812721 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Optive
Description: One drop will be instilled into each eye once
Study NCT00812721 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Refresh Moderate/Severe
Description: One drop will be instilled into each eye once
Study NCT00812721 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Systane
Description: One drop will be instilled into each eye once
Study NCT00812721 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Systane Ultra
Description: One drop will be instilled into each eye once
Study NCT02190552 — intervention group
Intervention type: DEVICE
Intervention: EmboTrap® Revascularization Device
Study NCT02602353 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Loxoprofen Pain Patch
Description: One Loxoprofen Pain Patch (active NSAID) applied once daily for 3 days
Study NCT02602353 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo Patch
Description: One Placebo Patch applied daily for 3 days
Study NCT02602353 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: No Treatment
Description: No Treatment for 3 days
Study NCT00605566 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sorafenib
Description: During a run-in period, patient will start taking 50 mg QD of oral cyclophosphamide and 200 mg BID of sorafenib. On day 8 of run-in the patient will be evaluated for toxicity. In the absence of toxicity, the patient will be escalated to sorafenib 400 mg BID and continue on daily 50 mg of cyclophosphamide, or the patient will be informed to continue on sorafenib 200 mg BID and cyclophosphamide 50 mg QD. Dose escalation procedure will be repeated every 2 weeks until unable to tolerate the study drug, or a maximum of 800 mg BID is reached, or achievement of > 90% inhibition of phosphorylation of PDGFR/Raf axis in PBMC. After run-in period, patient begins cycle 1, each cycle will last 28 days. Both cyclophosphamide and sorafenib will be taken orally.
Study NCT00605566 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cyclophosphamide
Description: During a run-in period, patient will start taking 50 mg QD of oral cyclophosphamide and 200 mg BID of sorafenib. On day 8 of run-in the patient will be evaluated for toxicity. In the absence of toxicity, the patient will be escalated to sorafenib 400 mg BID and continue on daily 50 mg of cyclophosphamide, or the patient will be informed to continue on sorafenib 200 mg BID and cyclophosphamide 50 mg QD. Dose escalation procedure will be repeated every 2 weeks until unable to tolerate the study drug, or a maximum of 800 mg BID is reached, or achievement of > 90% inhibition of phosphorylation of PDGFR/Raf axis in PBMC. After run-in period, patient begins cycle 1, each cycle will last 28 days. Both cyclophosphamide and sorafenib will be taken orally.
Study NCT02185677 — intervention group
Intervention type: OTHER
Intervention: Clinical evaluation
Study NCT02185677 — intervention group
Intervention type: OTHER
Intervention: neuropsychological battery test
Study NCT02185677 — intervention group
Intervention type: OTHER
Intervention: MRI
Study NCT02185677 — intervention group
Intervention type: OTHER
Intervention: Actigraphy
Description: Actigraphy recording will be performed during 7 days after inclusion.
Study NCT01357109 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bosentan
Description: 62.5 mg bid for two weeks and 125 mg bid for two weeks
Study NCT01357109 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Matched placebo bid
Study NCT04700475 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: low level laser
Description: Laser will be performed with a GaAlAs diode laser at a wavelength of 808 nm, 100-mW output power, laser beam area of 0.03 cm2, and in continuous wave mode, three times a week, on alternate days. Laser therapy will be initiated before the first radiotherapy session and ended after the last session, totaling 21 sessions.~The total energy per session (56 J) will be divided into 14 irradiation points, as marked on the overlying skin (Fig.2). Each irradiation point received a dose of 4 J over an irradiation time of 40 s.~With exclusion of tumor area or area of removed tumor laser will be applied as following:~• Extra oral application: The laser will be used extraorally at eight points in the parotid glands (bilaterally, four points in each gland), at four points in the submandibular glands (bilaterally, two points in each gland~• Intraoral application: The will be used intraorally at two points in the sublingual glands bilaterally, one point in each gland .
Study NCT04700475 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: citric acid solution
Description: citric acid solution applied as a mouth rinse
Study NCT04700475 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: citric acid solution
Description: citric acid solution applied as a mouth rinse
Study NCT00263484 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: dexamethasone
Description: 20 mg, PO (orally) on days 1-4, 8-11 and 15-18 of each 21 day cycle. 6 Cycles: until progression or unacceptable toxicity develops.
Study NCT00263484 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: thalidomide
Description: 100 mg, PO (orally) on days 1-21 of each 21 day cycle. 6 Cycles: until progression or unacceptable toxicity develops.
Study NCT00263484 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: zoledronic acid
Description: 4 mg, IV (in the vein) on day 1 of each 21 day cycle. 6 Cycles: until progression or unacceptable toxicity develops.
Study NCT00469859 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: cytarabine
Description: given IV
Study NCT00469859 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: idarubicin
Description: Given IV
Study NCT00469859 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: lestaurtinib
Description: Given orally
Study NCT00996814 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Proactive Ethics Intervention
Description: The ethicist will: 1) meet with the patient or surrogate to assess the case and the decision-making capacity of the patient; 2) make an ethical diagnosis, framing the issues in easily understood ethical terms with the involved parties; 3) recommend the next steps, including measures to improve communication. The ethicist will help to articulate consensus or disagreement and either facilitate implementing the consensus or facilitate ways to address and resolve disagreements; 4) document the consultation in the patient's medical record, identifying the ethical issues identified, the steps taken to address those issues, the options and ethical rationales considered, the outcome and the future plan; 5) follow-up to provide ongoing support and record a follow up progress note in the chart; and 6) participate in evaluation.
Study NCT02970357 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: DIAPASON Questionnaire
Description: 50 item questionnaire of the French Youth Diabetes Association to evaluate one's theoretical knowledge about the diabetes disease. 6 main themes are evaluated :~* what is diabetes~* Monitoring~* Hypoglycemia and Hyperglycemia~* Nutrition~* Insuline
Study NCT02970357 — intervention group
Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: WHO-5
Description: 5 item questionnaire of the World Health Organization about quality of life
Study NCT02956356 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Control treatment + oral glucose
Description: Control granulates (maize starch and long-chain fatty acids) with powder; 75g oral glucose load
Study NCT02956356 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: SATIOSTAT treatment + oral glucose
Description: SATIOSTAT granulates (hydrocolloids (fibers) and long-chain fatty acids) with powder; 75g oral glucose load
Study NCT02956356 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Control treatment + meal intake
Description: Control granulates (maize starch and long-chain fatty acids) with powder; test meal (ham sandwiches: 50g bread, 10g butter, 29g ham (pork); 247 kcal/sandwich) and tap water)
Study NCT02956356 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: SATIOSTAT treatment + meal intake
Description: SATIOSTAT granulates (hydrocolloids (fibers) and long-chain fatty acids) with powder; test meal (ham sandwiches: 50g bread, 10g butter, 29g ham (pork); 247 kcal/sandwich) and tap water)
Study NCT04302649 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: peritoneal dialysate at 37°C temperature
Description: during a PET test, patients received peritoneal dialysate warmed at 37°C before infusion
Study NCT03717077 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: learned resourcefulness intervention
Description: The LR program includes: 1) Solving problem strategy, 2) Organizing daily actions, 3) Using self-regulation, 4) Reframing positive situations, 5) Changing negative self-thinking, 6) Exploring new thinking and skills. It is conducted one time per week.
Study NCT03389425 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: simplified intervention to modify physical activity, lifestyle, and eating behavior
Description: 16 week, behavioural weightloss intervention.
Study NCT02210208 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Mepitel® Ag
Description: A soft silicone wound contact layer that allows exudates to pass vertically into a secondary absorbent dressing. The product provides fixation and protection of the tissues and has antimicrobial properties.~This silicone net dressing will be used to prevent lifting and adherence of skin grafts to the dressings, as well as to prevent pain, and promote healing.
Study NCT02210208 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Mepilex® Transfer Ag
Description: Mepilex® Transfer Ag is a soft silicone wound contact layer that absorbs and transfers exudate, maintains a moist wound healing environment and has antimicrobial properties.~Mepilex® Transfer Ag consists of a Safetac® adhesive layer and compressed polyurethane foam containing silver sulphate and activated carbon. Safetac® is a unique adhesive technology that minimizes pain to patients and trauma to wounds and the surrounding skin. It minimizes risk for maceration by sealing the wound margins; ensuring exudate does not spread to the surrounding skin.
Study NCT00605995 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Simvastatin
Description: 20 mg taken orally once daily for the first 4 weeks. Dosage will be increased to 40 mg/day at the end of week 4.
Study NCT03901508 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: TDCS
Description: 20 minutes, 2 electrodes (C3/FP2)
Study NCT03901508 — intervention group
Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: TDCS
Description: 20 minutes, 2 electrodes (C3/FP2)
Study NCT05080361 — intervention group
Intervention type: DRUG
Intervention: BRAF inhibitor
Description: Reports of adverse events occurring in patients treated with at least one BRAFi or MEKi as reported in the individual case safety reports.
Study NCT02401061 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PRTX-100
Description: Four weekly infusions of PRTX-100 at a level of 1 (3, 6,12, 18, or 24) microgram of PRTX-100 per kilogram of patient weight, infused over 30 minutes, followed by four hours of observation.
Study NCT02772809 — intervention group
Intervention type: DEVICE
Group type: OTHER
Intervention: Haptic Robot Therapy with Games
Description: Commercial Joystick and Wheels Plus the Haptic TheraDrive Robot will be used. Haptic Theradrive is a low-cost robotic system for post-stroke upper extremity rehabilitation. The system uses off-the-shelf computer gaming wheels with force feedback to help reduce motor impairment and improve function in the arms of stroke survivors.
Study NCT02238938 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: en-bloc resection
Description: En- bloc resection after marking by use of different customary endoscopic knifes including combining devices as hybrid knife to cut down the lesion. After submucosal injection of liquid (saline or equivalent) to elevate the tissue it will be dissected and removed by a snare of adequate size solitarily.
Study NCT02238938 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: piecemeal resection
Description: Piecemeal resection is done by snare after marking and submucosal injection of saline or equivalent liquids. Small leftover adenoma tissue will be resected thoroughly by snare or forceps.~After three months, an APC therapy will follow any piecemeal resection, if necessary, another resection of leftover adenoma will be done.
Study NCT00605995 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Simvastatin
Description: 20 mg taken orally once daily for the first 4 weeks. Dosage will be increased to 40 mg/day at the end of week 4.
Study NCT02841345 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: behavioral and fMRI
Description: The experience will include 3 sessions. Each session will consist of the presentation of a pseudo-random sequence of 24 black and white images of negative emotional natural scenes, 24 positive emotional situations and 24 neutral emotional situations.~* In the first session, participants will carry out an emotional assessment task: it will show at the end of each test his emotional feeling - pleasant, unpleasant or nothing - using a joystick.~* In a second session, the participant will perform a motor task decision: it will show at the end of each test the tendency to action he would handle the situation actually using 3 buttons également- approach withdrawal or neither one nor the other.~* In the third session, the participant will perform a simple visual perception task. To be comparable to the engine plane with the other sessions, a non-categorical motor task will be requested from participants.
Study NCT06462274 — intervention group
Intervention type: OTHER
Intervention: body sample collection and imaging scan
Study NCT01304771 — intervention group
Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Synbiotic AKSB
Description: AKSB is a novel synbiotic that contains a probiotic bacterium (Enterococcus faecium, microencapsulated SF68 or Ventrux ME 30), a probiotic yeast (Saccharomyces cerevisiae, Lynside® Pro-Lay 1), and a prebiotic (fructo-oligosaccharide \[FOS\], NutraFlora®).
Study NCT01304771 — intervention group
Intervention type: BIOLOGICAL
Group type: PLACEBO_COMPARATOR
Intervention: Synbiotic AKSB
Description: AKSB is a novel synbiotic that contains a probiotic bacterium (Enterococcus faecium, microencapsulated SF68 or Ventrux ME 30), a probiotic yeast (Saccharomyces cerevisiae, Lynside® Pro-Lay 1), and a prebiotic (fructo-oligosaccharide \[FOS\], NutraFlora®).
Study NCT01491542 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: INFUSE® Bone Graft/MASTERGRAFT® Granules/CD HORIZON®
Description: The INFUSE® Bone Graft component of the investigational device consists of recombinant human Bone Morphogenetic Protein-2(rhBMP-2) and an absorbable collagen sponge (ACS)carrier. The MASTERGRAFT® Granules will be used as a type of bulking agent to provide compression resistance.
Study NCT01491542 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Autogenous Bone / CD HORIZON® Spinal System
Description: The control will be autogenous bone taken from the iliac crest of the patient and placed bilaterally across two adjacent transverse processes and used in conjunction with the CD HORIZON® Spinal System.
Study NCT03344016 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Contact by clinical center
Description: Patients will be acitvely contacted by the clinical center for follow-up procedure
Study NCT01538225 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sativex®
Description: THC:CBD 1:1 ratio oromucosal spray. A titration period is required to reach optimal dose. The number and timing of sprays may vary between patients.~Duration: 2 weeks
Study NCT01538225 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Placebo~Same frequency and dosage form as Sativex.~Duration: 2 weeks
Study NCT02104505 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Gamma Tocopherol 700 mg capsules,
Description: 2 capsules daily
Study NCT02104505 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Safflower oil capsules
Study NCT00610805 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Preventive Cardiology
Description: Patients will receive those interventions recommended by the Preventive Cardiologist. This may include: exercise, electrocardiogram, specialized blood testing, blood pressure monitoring, nutrition counseling, smoking cessation counseling, and pharmacotherapy for hypercholesterolemia, hypertension, and blood sugar abnormalities.
Study NCT00610805 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Usual Care
Description: Participants will receive usual care per their primary care physician.
Study NCT01904136 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Allogeneic Hematopoietic Stem Cell Transplantation
Description: Undergo allogeneic PBSC or bone marrow transplant